Skip to main content
TipRanks
Go Ultimate75% OFF

Xilio Therapeutics (XLO) Ratios

222 Followers

Xilio Therapeutics Ratios

XLO's free cash flow for Q3 2026 was $-13.85M. For the 2026 fiscal year, XLO's free cash flow was decreased by $-58.00K and operating cash flow was $-13.79M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio2.582.213.025.8915.85
Quick Ratio2.582.213.025.8915.85
Cash Ratio2.442.032.805.7015.50
Solvency Ratio-0.28-1.06-3.09-2.58-2.05
Operating Cash Flow Ratio-0.09-0.67-4.30-3.59-6.32
Short-Term Operating Cash Flow Coverage0.000.00-20.70-11.36-91.45
Net Current Asset Value$ 25.61M$ 6.76M$ 24.03M$ 90.98M$ 166.35M
Leverage Ratios
Debt-to-Assets Ratio0.040.110.190.140.09
Debt-to-Equity Ratio0.200.460.310.190.11
Debt-to-Capital Ratio0.160.320.240.160.10
Long-Term Debt-to-Capital Ratio0.000.000.000.030.05
Financial Leverage Ratio4.394.041.651.321.20
Debt Service Coverage Ratio0.00-580.01-23.30-13.09-49.70
Interest Coverage Ratio0.00-605.820.000.00-125.07
Debt to Market Cap0.000.000.220.130.02
Interest Debt Per Share0.832.160.420.730.78
Net Debt to EBITDA3.900.810.431.152.41
Profitability Margins
Gross Profit Margin96.48%100.00%0.00%0.00%0.00%
EBIT Margin-80.05%-940.18%0.00%0.00%0.00%
EBITDA Margin-76.53%-914.27%0.00%0.00%0.00%
Operating Profit Margin-95.92%-954.95%0.00%0.00%0.00%
Pretax Profit Margin-80.05%-918.05%0.00%0.00%0.00%
Net Profit Margin-80.05%-918.05%0.00%0.00%0.00%
Continuous Operations Profit Margin-80.05%-918.05%0.00%0.00%0.00%
Net Income Per EBT100.00%100.00%100.00%100.00%100.00%
EBT Per EBIT83.45%96.14%96.55%98.96%101.01%
Return on Assets (ROA)-22.65%-81.94%-125.40%-63.39%-34.21%
Return on Equity (ROE)-99.33%-330.95%-207.47%-83.51%-40.88%
Return on Capital Employed (ROCE)-42.66%-138.27%-175.97%-75.52%-35.94%
Return on Invested Capital (ROIC)-42.09%-134.62%-163.89%-70.96%-35.79%
Return on Tangible Assets-22.65%-81.94%-125.40%-63.39%-34.21%
Earnings Yield-46.78%-113.97%-505.22%-119.73%-17.32%
Efficiency Ratios
Receivables Turnover8.750.000.000.000.00
Payables Turnover0.490.000.000.000.48
Inventory Turnover0.000.000.000.000.00
Fixed Asset Turnover5.570.700.000.000.00
Asset Turnover0.280.090.000.000.00
Working Capital Turnover Ratio0.720.190.000.000.00
Cash Conversion Cycle-708.670.000.000.00-765.55
Days of Sales Outstanding41.700.000.000.000.00
Days of Inventory Outstanding0.000.000.000.000.00
Days of Payables Outstanding750.370.000.000.00765.55
Operating Cycle41.700.000.000.000.00
Cash Flow Ratios
Operating Cash Flow Per Share-0.60-4.81-2.50-2.76-2.95
Free Cash Flow Per Share-0.66-4.82-2.51-2.83-2.99
Dividend Paid and CapEx Coverage Ratio-9.64-510.50-141.19-40.56-73.41
Capital Expenditure Coverage Ratio-9.64-510.50-141.19-40.56-73.41
Operating Cash Flow Coverage Ratio-0.72-2.26-5.99-3.80-3.89
Operating Cash Flow to Sales Ratio-0.11-2.900.000.000.00
Free Cash Flow Yield-7.36%-36.03%-456.97%-105.30%-18.70%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-2.14-0.88-0.20-0.84-5.77
Price-to-Sales (P/S) Ratio1.718.060.000.000.00
Price-to-Book (P/B) Ratio2.122.900.410.702.36
Price-to-Free Cash Flow (P/FCF) Ratio-13.59-2.78-0.22-0.95-5.35
Price-to-Operating Cash Flow Ratio-15.00-2.78-0.22-0.97-5.42
Price-to-Earnings Growth (PEG) Ratio0.030.010.02-0.05-0.16
Enterprise Value Multiple1.66-0.070.230.31-3.53
Enterprise Value-55.68M3.95M-18.12M-26.76M260.42M
EV to EBITDA1.66-0.070.230.31-3.53
EV to Sales-1.270.620.000.000.00
EV to Free Cash Flow10.11-0.210.260.34-3.18
EV to Operating Cash Flow11.15-0.220.260.35-3.22
Tangible Book Value Per Share4.224.601.343.866.78
Shareholders’ Equity Per Share4.224.601.343.866.78
Tax and Other Ratios
Effective Tax Rate0.000.000.000.000.00
Revenue Per Share5.241.660.000.000.00
Net Income Per Share-4.19-15.24-2.78-3.22-2.77
Tax Burden1.001.001.001.001.00
Interest Burden1.000.980.970.991.01
Research & Development to Revenue1.286.500.000.000.00
SG&A to Revenue0.683.910.000.000.00
Stock-Based Compensation to Revenue0.161.010.000.000.00
Income Quality0.140.320.900.861.07

Currency in USD